AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Evogene Ltd. Regulatory Filings 2021

Apr 19, 2021

6785_rns_2021-04-19_bce6035a-893b-4a5f-9c64-8d8c6a68e8d3.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Biomica to Present at Jefferies Microbiome-Based Therapeutics Summit, on April 22nd, 2021

(Virtual Conference)

Rehovot, Israel – April 19, 2021 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced that Dr. Elran Haber, Chief Executive Officer of Biomica, will present at the Jefferies Microbiome-Based Therapeutics Summit being held on Thursday, April 22, 2021.

Dr. Haber will be available for one-on-one meetings during the summit.

A Pre-Recording of the Presentation will be made available on Thursday, April 22, 2021.

***

About Biomica:

Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN). For more information, please visit www.biomicamed.com.

Contact:

Rivka Neufeld/ Aviva Banczewski Investor Relations and Public Relations Manager E: [email protected] T: +972-8-931-1900